Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus BioPharma, Inc.'s Aerosol Statin Formulation
5/12/2009 10:32:04 AM
More...
|
Working with U.S. Department of Defense, Canopus BioPharma, Inc. Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300
11/4/2008 9:02:16 AM
More...
|
Canopus BioPharma, Inc. Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine
11/3/2008 6:31:44 AM
More...
|
Canopus BioPharma, Inc. and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
8/12/2008 11:27:23 AM
More...
|
CB1400, Patented by Canopus BioPharma, Inc., Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
6/23/2008 7:43:55 AM
More...
|
B1400, Patented by Canopus BioPharma, Inc., Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux)
6/19/2008 10:08:43 AM
More...
|
Canopus BioPharma, Inc. Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement with Wisconsin Alumni Research Foundation (WARF)
6/18/2008 10:05:11 AM
More...
|
Canopus BioPharma, Inc. to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo
5/15/2008 10:15:29 AM
More...
|
Canopus BioPharma, Inc. Engages Pullan Consulting to Commence the Formation of Drug Development and Licensing Partnerships
5/1/2008 9:34:13 AM
More...
|
Canopus BioPharma, Inc. Selected to Present its Drug Candidate for HIV/AIDS Treatment at the Global Summit on AIDS and the Church
12/3/2007 11:59:48 AM
More...
|
|